» Articles » PMID: 27672125

Contrasting Expression Pattern of RNA-sensing Receptors TLR7, RIG-I and MDA5 in Interferon-positive and Interferon-negative Patients with Primary Sjögren's Syndrome

Overview
Journal Ann Rheum Dis
Specialty Rheumatology
Date 2016 Sep 28
PMID 27672125
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The interferon (IFN) type I signature is present in over half of patients with primary Sjögren's syndrome (pSS) and associated with higher disease-activity and autoantibody presence. Plasmacytoid dendritic cells (pDCs) are considered as the main source of enhanced IFN type I expression. The objective of this study was to unravel the molecular pathways underlying IFN type I bioactivity in pDCs of patients with pSS.

Methods: Blood samples from 42 healthy controls (HC) and 115 patients with pSS were stratified according to their IFN type I signature. CD123BDCA4 pDCs and CD14 monocytes were isolated from peripheral blood mononuclear cells (PBMCs). Genome-wide microarray analysis was conducted on sorted pDCs in a small sample set, followed by validation of differentially expressed genes of interest in pDCs and monocytes.

Results: We found an upregulation of endosomal toll-like receptor (TLR) 7, but not TLR9, in IFN-positive (IFNpos) pDCs (p<0.05) and monocytes (p=0.024). Additionally, the downstream signalling molecules MyD88, RSAD2 and IRF7 were upregulated, as were the cytoplasmic RNA-sensing receptors DDX58/retinoic acid inducible gene-I (RIG-I) and IFIH1/melanoma differentiation associated gene-5 (MDA5). In vitro triggering of the TLR7-pathway in HC PBMCs induced upregulation of DDX58/RIG-I and IFIH1/MDA5, and downregulated TLR9. The upregulation of TLR7, its downstream signalling pathway, DDX58/RIG-I and IFIH1/MDA5 were confined to patients with IFN-positive pSS. IFN-negative patients had a contrasting expression pattern-TLR7 normal, and decreased TLR9, RIG-I and MDA5.

Conclusions: Here we conclude a contrasting expression pattern of the RNA-sensing receptors TLR7, RIG-I and MDA5 in pDCs and monocytes of patients with IFNpos pSS. This profile could explain the pathogenic IFN production and might reveal novel therapeutic targets in these patients.

Citing Articles

Sex-specific differences in primary Sjögren's disease.

Punnanitinont A, Kramer J Front Dent Med. 2025; 4:1168645.

PMID: 39916928 PMC: 11797869. DOI: 10.3389/fdmed.2023.1168645.


Mechanisms underlying sex differences in autoimmunity.

Fairweather D, Beetler D, McCabe E, Lieberman S J Clin Invest. 2024; 134(18).

PMID: 39286970 PMC: 11405048. DOI: 10.1172/JCI180076.


Transcriptomics explores potential mechanisms for the development of Primary Sjogren's syndrome to diffuse large B-cell lymphoma in B cells.

Xu Y, Han J, Fan Z, Liang S BMC Immunol. 2024; 25(1):53.

PMID: 39080525 PMC: 11287849. DOI: 10.1186/s12865-024-00646-8.


Advances in cellular and molecular pathways of salivary gland damage in Sjögren's syndrome.

Qi W, Tian J, Wang G, Yan Y, Wang T, Wei Y Front Immunol. 2024; 15:1405126.

PMID: 39050857 PMC: 11266040. DOI: 10.3389/fimmu.2024.1405126.


TLR7 activation of age-associated B cells mediates disease in a mouse model of primary Sjögren's disease.

Punnanitinont A, Kasperek E, Zhu C, Yu G, Miecznikowski J, Kramer J J Leukoc Biol. 2023; 115(3):497-510.

PMID: 37930711 PMC: 10990110. DOI: 10.1093/jleuko/qiad135.